RV Invest

Alex holds PhD degree in computational chemistry and MBA from Mannheim Business School. Alex brings more than 10 years of experience in the biotech space, being a co-founder of drug development startup himself and then moving to the VC side. He successfully invested in Biotech and Medtech startups from a VC fund RBV Capital and from CVC arm of tier 1 reinsurance company SCOR.

Nick holds an MBA from SDA Bocconi school of management and studied Human Physiology at the University of Colorado. He is currently CEO of OncoBeta, a Radiation Oncology company, and acts as Board member / Board observer in different companies in healthcare. He is part of the 3rd generation of ownership in Vetter Pharma.

Timo holds a Diploma in Business Administration from DHBW Mannheim / Bachelor degree from Open University London as well as a MBA from WWU Muenster (CUR). He has gained broad experience in finance management throughout roles within different international companies including Merck and Vetter Pharma.

Carla graduated in Business Administration from ESADE and holds an MSc in Applied Neurosciences from King’s College London. She has 4 years of experience supporting innovative technology startups through her roles in the consulting firm Gartner, the biotech startup accelerator BaseLaunch and the impact-driven VC fund LBS. Her responsibilities included the search for new investment opportunities, the analysis of companies prior to investment and the support of start-ups’ growth and financing efforts.

Lu Zheng holds a PhD in Neuroscience from the Swiss Federal Institute of Technology Lausanne (EPFL) and an MBA from St. Gallen University. She has gained industry experience at Nestlé Research Center in clinical development and at Syneos Health Consulting in drug commercialization strategy. Prior to joining RVI, Lu gained venture capital experience with +ND Capital and Ysios Capital.

Dr. Susanne Schaffert has 25 years of experience in Pharmaceuticals, specializing in Oncology. As the former President of Novartis Oncology, she led a broad portfolio, including the first CAR-T cell therapy in hematology and the launch of the first two radio ligand therapies in solid tumors. She managed 10,000 associates, achieving $15bn in annual sales. Recognized by Fortune as one of the Top 100 Most Powerful Women in 2019 and 2020, she now serves on multiple biotech boards, including Merck Group, Incyte Corporation, Novo Holdings, Galapagos, ARTBio Inc., and Vetter Pharma. She holds a PhD in Chemistry from the University of Erlangen, Germany.

Patrick Lally has over 15 years of healthcare investing experience. As a Partner at Petrichor, he oversees all investing activities, including origination, diligence, and asset management. He serves on the boards of Aurion Biotech, Corneagen, ITM, Persivia, and Vero. Previously, Patrick invested in healthcare special situations and structured finance at OrbiMed Advisors and focused on healthcare investments at Fortress Investment Group’s Drawbridge Special Opportunities Fund. He began his career at Barclays Capital in capital markets and leveraged finance. He holds an M.B.A. from Wharton and an A.B. in Molecular Biology from Princeton.

Alexey A. Lugovskoy, PhD is President and Chief Executive Officer of Diagonal Therapeutics, Entrepreneur-in-Residence at Atlas Ventures and Associate Editor of mAbs. He formerly served as Chief Operating Officer at Dragonfly, Chief Development Officer at Morphic, Vice President of Therapeutics at Merrimack Pharmaceuticals and Associate Director of Drug Discovery at Biogen. He has received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University, an M.Sc. in Molecular Biophysics, and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.